Immunoinformatic Based Identification of Cytotoxic T Lymphocyte Epitopes from the Indian Isolate of SARS-CoV-2

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 26

PMID 33633155

Citations 4

Authors

Viswajit Mulpuru

Nidhi Mishra

Affiliations

Soon will be listed here.

Abstract

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has turned into a pandemic with about thirty million confirmed cases worldwide as of September 2020. Being an airborne infection, it can be catastrophic to populous countries like India. This study sets to identify potential cytotoxic T lymphocyte (CTL) epitopes in the SARS-CoV-2 Indian isolate which can act as an effective vaccine epitope candidate for the majority of the Indian population. The immunogenicity and the foreignness of the epitopes towards the human body have to be studied to further confirm their candidacy. The top-scoring epitopes were subjected to molecular docking studies to study their interactions with the corresponding human leukocyte antigen (HLA) system. The CTL epitopes were observed to bind at the peptide-binding groove of the corresponding HLA system, indicating their potency as an epitope candidate. The candidacy was further analyzed using sequence conservation studies and molecular dynamics simulation. The identified epitopes can be subjected to further studies for the development of the SARS-CoV-2 vaccine.

Citing Articles

Insight into Protein Engineering: From Modelling to Synthesis.

Balakrishnan A, Mishra S, Georrge J Curr Pharm Des. 2024; 31(3):179-202.

PMID: 39354773 DOI: 10.2174/0113816128349577240927071706.

New Short RNA Motifs Potentially Relevant in the SARS-CoV-2 Genome.

Fuertes M, Alonso C Curr Genomics. 2023; 23(6):424-440.

PMID: 37920558 PMC: 10173420. DOI: 10.2174/1389202924666230202152351.

Cromolyn prevents cerebral vasospasm and dementia by targeting WDR43.

Wang X, Kong F, Lin Z Front Aging Neurosci. 2023; 15:1132733.

PMID: 37122373 PMC: 10133528. DOI: 10.3389/fnagi.2023.1132733.

Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches.

Samad A, Meghla N, Nain Z, Karpinski T, Rahman M Cancer Immunol Immunother. 2022; 71(10):2535-2548.

PMID: 35294591 PMC: 8924353. DOI: 10.1007/s00262-022-03181-w.

Development of an indirect ELISA to specifically detect antibodies against African swine fever virus: bioinformatics approaches.

Gao Z, Shao J, Zhang G, Ge S, Chang Y, Xiao L Virol J. 2021; 18(1):97.

PMID: 33952293 PMC: 8097255. DOI: 10.1186/s12985-021-01568-2.

References

Barker W, Garavelli J, Huang H, McGarvey P, Orcutt B, Srinivasarao G . The protein information resource (PIR). Nucleic Acids Res. 1999; 28(1):41-4. PMC: 102418. DOI: 10.1093/nar/28.1.41. View

Rock K, Reits E, Neefjes J . Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016; 37(11):724-737. PMC: 5159193. DOI: 10.1016/j.it.2016.08.010. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

De Groot A, Moise L, Liu R, Gutierrez A, Tassone R, Bailey-Kellogg C . Immune camouflage: relevance to vaccines and human immunology. Hum Vaccin Immunother. 2014; 10(12):3570-5. PMC: 4514035. DOI: 10.4161/hv.36134. View

Xia S, Tao Y, Cui L, Yu Y, Xu S . MHC Class I Molecules Exacerbate Viral Infection by Disrupting Type I Interferon Signaling. J Immunol Res. 2019; 2019:5370706. PMC: 6754968. DOI: 10.1155/2019/5370706. View

Kar T, Narsaria U, Basak S, Deb D, Castiglione F, Mueller D . A candidate multi-epitope vaccine against SARS-CoV-2. Sci Rep. 2020; 10(1):10895. PMC: 7331818. DOI: 10.1038/s41598-020-67749-1. View

Bhattacharya M, Sharma A, Patra P, Ghosh P, Sharma G, Patra B . Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. J Med Virol. 2020; 92(6):618-631. PMC: 7228377. DOI: 10.1002/jmv.25736. View

Petrova G, Ferrante A, Gorski J . Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol. 2012; 32(4):349-72. PMC: 3595599. DOI: 10.1615/critrevimmunol.v32.i4.50. View

Cameron B, Gerry A, Dukes J, Harper J, Kannan V, Bianchi F . Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013; 5(197):197ra103. PMC: 6002776. DOI: 10.1126/scitranslmed.3006034. View

10.

Francisco R, Buhler S, Nunes J, Bitarello B, Franca G, Meyer D . HLA supertype variation across populations: new insights into the role of natural selection in the evolution of HLA-A and HLA-B polymorphisms. Immunogenetics. 2015; 67(11-12):651-63. PMC: 4636516. DOI: 10.1007/s00251-015-0875-9. View

11.

Chen H, Tang L, Yu X, Zhou J, Chang Y, Wu X . Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infect Dis Poverty. 2020; 9(1):88. PMC: 7395940. DOI: 10.1186/s40249-020-00713-3. View

12.

Zaheer T, Waseem M, Waqar W, Arshad Dar H, Shehroz M, Naz K . Anti-COVID-19 multi-epitope vaccine designs employing global viral genome sequences. PeerJ. 2020; 8:e9541. PMC: 7409810. DOI: 10.7717/peerj.9541. View

13.

Crooks G, Hon G, Chandonia J, Brenner S . WebLogo: a sequence logo generator. Genome Res. 2004; 14(6):1188-90. PMC: 419797. DOI: 10.1101/gr.849004. View

14.

Grifoni A, Sidney J, Zhang Y, Scheuermann R, Peters B, Sette A . A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020; 27(4):671-680.e2. PMC: 7142693. DOI: 10.1016/j.chom.2020.03.002. View

15.

Vita R, Mahajan S, Overton J, Dhanda S, Martini S, Cantrell J . The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2018; 47(D1):D339-D343. PMC: 6324067. DOI: 10.1093/nar/gky1006. View

16.

Madeira F, Park Y, Lee J, Buso N, Gur T, Madhusoodanan N . The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 2019; 47(W1):W636-W641. PMC: 6602479. DOI: 10.1093/nar/gkz268. View

17.

Elbe S, Buckland-Merrett G . Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2019; 1(1):33-46. PMC: 6607375. DOI: 10.1002/gch2.1018. View

18.

Croft N, Smith S, Pickering J, Sidney J, Peters B, Faridi P . Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci U S A. 2019; 116(8):3112-3117. PMC: 6386720. DOI: 10.1073/pnas.1815239116. View

19.

Laskowski R, Swindells M . LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011; 51(10):2778-86. DOI: 10.1021/ci200227u. View

20.

Calis J, Maybeno M, Greenbaum J, Weiskopf D, De Silva A, Sette A . Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013; 9(10):e1003266. PMC: 3808449. DOI: 10.1371/journal.pcbi.1003266. View